---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Bradykinin b2 receptor antagonists"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Bradykinin b2 receptor antagonists. Topics: Icatibant: receptor antagonism, Icatibant: FDA-approved indication, Icatibant: dosing and maximum number of doses, Icatibant: self-administration, and 11 further topics. 15 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/bradykinin-b2-receptor-antagonists"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Bradykinin b2 receptor antagonists

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Bradykinin B2 Receptor Antagonists

<a id="topic-2.2.2.1.2-1"></a>

### Icatibant: receptor antagonism

> “a specific and selective competitive antagonist of the bradykinin B2 receptor”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.2-2"></a>

### Icatibant: FDA-approved indication

> “FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.”
> “Safety and effectiveness in pediatric patients below the age of 18 years have not been established.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Icatibant: dosing and maximum number of doses

> “The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur.”
> “No more than 3 doses may be administered in any 24 hour period.”
> “FIRAZYR injection is supplied in a prefilled syringe delivering 30 mg icatibant.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### Icatibant: self-administration

> “Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional”
> “Self-administration of FIRAZYR by 56 patients was assessed in an open label trial.”
> “Patients who administered FIRAZYR during an acute attack of HAE had a median time to 50% reduction from the pretreatment composite 3-itemVAS score of 2.6 hours.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Icatibant: injection-site reactions

> “The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials.”
> “Injection site reactions are reported in most patients after administration of FIRAZYR.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

> “It generally has an adequate safety and tolerability profile, although mild injection site reactions may occur in up to 97% of cases.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-6"></a>

### Icatibant: laryngeal attacks and interaction with ACE inhibitors

> “Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.”
> “FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

### FAST-3: results as described in the FDA label

> “Trial 1 was a randomized, placebo-controlled, double-blind, parallel-group study of 98 adult patients with a median age of 36 years.”
> “The median time to 50% reduction in symptoms for patients with cutaneous or abdominal attacks treated with FIRAZYR (n=43) compared to placebo (n=45) was 2.0 hours [95% CI 1.5, 3.0] versus 19.8 hours [95% CI 6.1, 26.3], respectively (p<0.001).”
> “In Trial 1, the median times to almost complete symptom relief were 8.0 versus 36.0 hours for FIRAZYR and placebo, respectively.”
> “In terms of rescue medication use, 3/43 (7%) patients treated with FIRAZYR used additional rescue medication in comparison to 18/45 (40%) patients treated with placebo.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### FAST-3: published primary and key secondary endpoints

> “Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P < .001, primary endpoint), onset of primary symptom relief (1.5 vs 18.5 hours; P < .001, key secondary endpoint), or almost complete symptom relief (8.0 vs 36.0 hours; P = .012) and provided a shorter time to initial symptom relief (0.8 vs 3.5 hours; P < .001).”
> “All icatibant-treated subjects experienced injection site reactions, but none reported clinically relevant changes in safety parameters or serious AEs.”

Source: [Lumry et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22123383/)

<a id="topic-2.2.2.1.2-9"></a>

### FAST-1 and FAST-2: icatibant compared with placebo and with tranexamic acid

> “In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days.”
> “In FAST-1, the primary end point, the median time to clinically significant relief of the index symptom, was 2.5 hours in the icatibant group versus 4.6 hours in the placebo group (P = 0.14) (Table 2 and Fig. 1A).”
> “In FAST-2, the median time to clinically significant relief of the index symptom was 2.0 hours with icatibant versus 12.0 hours with tranexamic acid (P<0.001) (Table 2 and Fig. 1B).”
> “The median time to almost complete relief of symptoms was 8.5 hours with icatibant versus 19.4 hours with placebo (P = 0.08) in FAST-1 (Table 2 and Fig. 2A) and 10.0 hours with icatibant versus 51.0 hours with tranexamic acid (P<0.001) in FAST-2 (Table 2 and Fig. 2B).”

Source: [Cicardi et al. (2010a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4662377/)

<a id="topic-2.2.2.1.2-10"></a>

### Icatibant: treatment of recurrent attacks in open-label extensions

> “A total of 225 patients were treated with 1,076 doses of 30 mg FIRAZYR for 987 attacks of acute HAE in these trials.”
> “The majority (93%) of these attacks of HAE were treated with a single dose of FIRAZYR.”
> “A total of 60 patients with laryngeal attacks were treated with FIRAZYR in the controlled trials.”
> “Efficacy results were similar to those observed for non-laryngeal (cutaneous and abdominal) sites of attack.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-11"></a>

### Generic icatibant: SAJAZIR indication and dosing

> “SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.”
> “The recommended dose of SAJAZIR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “SAJAZIR is supplied in a prefilled syringe delivering 30 mg icatibant.”

Source: [Cycle SAJAZIR prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c)

<a id="topic-2.2.2.1.2-12"></a>

### Generic icatibant: number of approved generic products

> “Seven generic forms of icatibant have been approved in the U.S.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The recent approval of several generics for icatibant have decreased cost and hopefully will allow broader access.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-13"></a>

### Icatibant: timing of treatment and attack duration in the Icatibant Outcome Survey

> “The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant.”
> “Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).”
> “Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.”
> “The proportion of attacks treated within 1 hour after attack onset was twice as high for self-administrators as for those who received HCP-administered icatibant (44% attacks versus 22% attacks, respectively; p = 0.001) (Figure 4).”

Source: [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)

<a id="topic-2.2.2.1.2-14"></a>

### Icatibant: guideline recommendation and redosing compared with C1 esterase inhibitor

> “Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.”
> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-15"></a>

### Deucrictibant: oral bradykinin B2 receptor antagonist in development

> “Deucrictibant is the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of hereditary angioedema attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
